The ALINA trial (NCT04302025), which looked at stage IB-IIIA ALK+ NSCLC patients, showed significant DFS in alectinib used for 2 years after surgery compared to chemotherapy in both stage II-IIIA and ITT populations[153]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.